Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
Inflammatory Bowel Disease II: Crohn's Disease01:30

Inflammatory Bowel Disease II: Crohn's Disease

Introduction
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by transmural...
Inflammatory Bowel Disease III: Crohn's Disease01:25

Inflammatory Bowel Disease III: Crohn's Disease

Crohn’s disease is a chronic, relapsing form of inflammatory bowel disease characterized by segmental, transmural inflammation that can affect any part of the gastrointestinal tract. Its pathogenesis arises from a combination of genetic susceptibility, environmental exposures, epithelial barrier dysfunction, and immune dysregulation. Together, these factors lead to an exaggerated immune response against components of the gut microbiome.Genetic and Environmental InfluencesMultiple genetic...
Inflammatory Bowel Disease II: Ulcerative Colitis01:20

Inflammatory Bowel Disease II: Ulcerative Colitis

Ulcerative colitis is a chronic inflammatory disorder of the colon characterized by continuous mucosal inflammation that typically begins in the rectum and extends proximally in a uniform pattern. Its pathogenesis involves a complex interplay of genetic predisposition, immune dysregulation, and environmental influences. These factors converge to impair the colon’s epithelial defenses and promote an exaggerated inflammatory response against luminal contents.Breakdown of the Mucosal BarrierA...
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2 (COX-2),...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Anti-tumor necrosis factor α: originators <i>versus</i> biosimilars, comparison in clinical response assessment in a multicenter cohort of patients with inflammatory arthropathies.

Reumatismo·2023
Same author

Efficacy of a gluten-free diet in reducing the widespread pain index and symptom severity scale in patients affected by fibromyalgia.

Reumatismo·2023
Same author

Biclonal gammopathy of undetermined significance in a patient with systemic lupus erythematosus and antiphospholipid syndrome.

Reumatismo·2022
Same author

Efficacy of gluten-free diet in patients with rheumatoid arthritis.

Reumatismo·2021
Same author

Psoriatic spondyloarthritis and Sjögren syndrome: a casual association?

Reumatismo·2020
Same author

Spondylodiscitis (Andersson lesion) in psoriatic spondyloarthritis: a rare event successfully treated with an anti-TNF therapy.

Acta reumatologica portuguesa·2016

Related Experiment Video

Updated: Jul 8, 2026

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis
11:39

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis

Published on: July 11, 2013

[Diffused suberitrodermic psoriasis induced by infliximab].

V Bruzzese1

  • 1Dipartimento di Medicina ASL RM/A, UOC di Medicina Interna, Sezione di Reumatologia, Ospedale Nuovo Regina Margherita, Roma, Italia. vinbruzzese@tiscali.it

Reumatismo
|December 25, 2007
PubMed
Summary
This summary is machine-generated.

A young male with Crohn disease developed a paradoxical psoriasis eruption after Infliximab treatment. This case highlights potential links between anti-TNF therapy, INF-alpha expansion, and psoriasis induction.

Related Experiment Videos

Last Updated: Jul 8, 2026

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis
11:39

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis

Published on: July 11, 2013

Area of Science:

  • Immunodermatology
  • Gastroenterology
  • Rheumatology

Background:

  • Crohn disease and reactive spondylarthritis are inflammatory conditions often treated with anti-tumor necrosis factor (TNF) agents.
  • Infliximab is a biologic therapy targeting TNF-alpha, commonly used for inflammatory diseases.

Observation:

  • A young male patient with Crohn disease and reactive spondylarthritis received Infliximab (3 mg/kg).
  • Following the third Infliximab infusion, the patient developed a psoriasis eruption on the palms and soles.
  • The psoriasis subsequently disseminated to the trunk and limbs, presenting a sub-erythrodermic appearance.

Findings:

  • The patient experienced a paradoxical cutaneous adverse effect (psoriasis) during anti-TNF therapy.
  • This suggests a potential link between Infliximab treatment and the induction or exacerbation of psoriasis.
  • The pathogenesis may involve TNF-alpha inhibition leading to interferon-alpha (INF-alpha) expansion, a potential psoriasis inducer.

Implications:

  • This case underscores the importance of monitoring for paradoxical cutaneous reactions in patients receiving anti-TNF therapy.
  • Understanding the immunomodulatory effects of Infliximab is crucial for managing complex inflammatory conditions.
  • Further research into the mechanisms of anti-TNF-induced psoriasis is warranted to optimize treatment strategies.